BioAffinity Technologies (BIAF) Stock News
$BIAF · NASDAQ · 4 stories in 30 days$3.73
1D −5.93%1W −37.00%1M −50.94%
BORSA has published 4 stories on BioAffinity Technologies (BIAF) in the past 30 days. BORSA’s news read on BIAF is bullish at 60/100, +14 over 24 hours, based on 1 company event over the past 7 days. BIAF last closed at $3.90 on Oct 12, down 37.00% over five sessions and down 50.94% over the past month. BioAffinity Technologies’ next earnings report is scheduled for Friday, Nov 13.
The wire on $BIAF
newest first · updated · direct subject stories onlybioAffinity Technologies to present data on sputum test for asthma, COPD inflammation at CHEST 2026
bioAffinity Technologies will present research at CHEST 2026 showing its sputum-based test in development can measure multiple inflammatory biomarkers, including targets of biologic drugs like Tezspire, Dupixent, and Nucala. The test builds on the CyPath Lung platform. It is investigational and not yet available for clinical use.
bullish 65 · impact 30